Maureen E. Murphy

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• The biology of hypomorphic <i>TP53</i> variants and implications for clinical management

  Clinical Cancer Research · 2026-06-12

• A phylogeny-guided framework for decoding mechanisms of human endogenous retrovirus regulation in health and disease

  bioRxiv (Cold Spring Harbor Laboratory) · 2026-05-21

• Abstract 603: Variation at the R181 residue of p53 confers loss of p53 DNA binding cooperativity with the retention of mitochondrial-associated apoptosis.

  Cancer Research · 2026-04-03

• A Personalized Therapeutic Approach for Liver Cancers Expressing the African-Centric P47S Variant of <i>TP53</i>

  Molecular Cancer Research · 2026-03-19

• A quantitative, Bayesian-informed approach to gene-specific variant classification: Updated Expert Panel recommendations improve classification of TP53 germline variants for Li-Fraumeni syndrome

  UNC Libraries · 2025-12-17

• Table S3 from An African-Specific Variant of &lt;i&gt;TP5&lt;/i&gt;3 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression

  2025-12-11

• Supplementary Figures S1-S8 from An African-Specific Variant of &lt;i&gt;TP5&lt;/i&gt;3 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression

  2025-12-11

• Table S2 from An African-Specific Variant of &lt;i&gt;TP5&lt;/i&gt;3 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression

  2025-12-11

• Table S4 from An African-Specific Variant of &lt;i&gt;TP5&lt;/i&gt;3 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression

  2025-12-11

• Table S1 from An African-Specific Variant of &lt;i&gt;TP5&lt;/i&gt;3 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression

  2025-12-11

• Table S5 from An African-Specific Variant of &lt;i&gt;TP5&lt;/i&gt;3 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression

  2025-12-11

• Table S6 from An African-Specific Variant of &lt;i&gt;TP5&lt;/i&gt;3 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression

  2025-12-11

• Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer

  Genes & Development · 2025-11-05 · 2 citations

• A quantitative, Bayesian-informed approach to gene-specific variant classification: Updated Expert Panel recommendations improve classification of TP53 germline variants for Li-Fraumeni syndrome

  Genome Medicine · 2025-10-22 · 5 citations

• Targeted citrullination enables p53 binding to non-canonical sites

  Molecular Cell · 2025-10-01 · 6 citations

• NAB2-STAT6 drives an EGR1-dependent neuroendocrine program in solitary fibrous tumors

  eLife · 2025-08-28

• Author response: NAB2-STAT6 drives an EGR1-dependent neuroendocrine program in solitary fibrous tumors

  2025-08-28

• Author Correction: P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting

  Scientific Reports · 2025-08-26

• LANA-dependent transcription-replication conflicts and R-loops at the terminal repeats (TR) correlate with KSHV episome maintenance

  PLoS Pathogens · 2025-08-18 · 1 citations

• Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated ApoptosisPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-08-13 · 1 citations